Latest Breaking News On - Tarsus pharmaceuticals inc - Page 8 : comparemela.com

Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements

Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAdrienne kempDavid nakasoneBobak azamianCorporate communicationsExchange commissionTarsus pharmaceuticals incChief executive officerBusiness highlightsCare providersMeibomian gland diseasePapulopustular rosaceaImportant safetyTarsus pharmaceuticalsElanco tiergesundheitTarsu form

Tarsus Pharmaceuticals Inc (TARS) Reports Robust Q4 and Full-Year 2023 Financial Results

Successful Launch of XDEMVY and Pipeline Advancements Mark Key Achievements

Bobak azamianTarsus pharmaceuticals incFinancial performancePharmaceuticals incChief executive officerBiopharmaceutical company

Tarsus Pharmaceuticals, Inc (TARS) Tops Q4 EPS by 7c

Tarsus Pharmaceuticals, Inc (TARS) Tops Q4 EPS by 7c
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Tarsus pharmaceuticals incTarsus pharmaceuticals

Tarsus Reports Strong Fourth Quarter And Full-Year 2023 Financial Results And Recent Business Achievements

Tarsus Reports Strong Fourth Quarter And Full-Year 2023 Financial Results And Recent Business Achievements
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Bobak azamianTarsus pharmaceuticals incChief executive officerBusiness highlightsCorporate updateCare providersMeibomian gland diseasePapulopustular rosaceaGlobal assessment

Tarsus Pharmaceuticals, Inc (NASDAQ:TARS) to Post FY2028 Earnings of $5 58 Per Share, HC Wainwright Forecasts

Tarsus Pharmaceuticals, Inc (NASDAQ:TARS) to Post FY2028 Earnings of $5 58 Per Share, HC Wainwright Forecasts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Zurcher kantonalbank zurich cantonalbankJosem trevejoBobakr azamianTower research capitalRoyal bankTarsus pharmaceuticals incChina universal asset management coNews ratings for tarsus pharmaceuticals dailyTarsus pharmaceuticals stockInstitutional investors weigh in on tarsus pharmaceuticalsGoldman sachs groupTarsus pharmaceuticalsFree reportTarsus pharmaceuticalResearch capitalUniversal asset management